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Abstract
Background: Mutation of the cystic fibrosis transmembrane-conductance regulator (CFTR) causes cystic fibrosis (CF) but not
all CF aspects can easily be explained by deficient ion transport. CF-inflammation provides one example but its
pathogenesis remains controversial. Here, we tested the simple but fundamental hypothesis that wild-type CFTR is needed
to suppress NF-kB activity.
Methodology/Principal Findings: In lung epithelial (H441) and engineered (H57) cell lines; we report that inflammatory
markers are significantly suppressed by wild-type CFTR. Transient-transfection of wild-type CFTR into CFTR-naı ¨ve H441 cells,
dose-dependently down-regulates both basal and Tumour Necrosis Factor-a evoked NF-kB activity when compared to
transfection with empty vector alone (p,0.01, n.5). This effect was also observed in CFTR-naı ¨ve H57-HeLa cells which
stably express a reporter of NF-kB activity, confirming that the CFTR-mediated repression of inflammation was not due to
variable reporter gene transfection efficiency. In contrast, H57 cells transfected with a control cyano-fluorescent protein
show a significantly elevated basal level of NF-kB activity above control. Initial cell seeding density may be a critical factor in
mediating the suppressive effects of CFTR on inflammation as only at a certain density (1610
5 cells/well) did we observe the
reduction in NF-kB activity. CFTR channel activity may be necessary for this suppression because the CFTR specific inhibitor
CFTRinh172 significantly stimulates NF-kB activity by ,30% in CFTR expressing 16HBE14o2 cells whereas pharmacological
elevation of cyclic-AMP depresses activity by ,25% below baseline.
Conclusions/Significance: These data indicate that CFTR has inherent anti-inflammatory properties. We propose that the
hyper-inflammation found in CF may arise as a consequence of disrupted repression of NF-kB signalling which is normally
mediated by CFTR. Our data therefore concur with in vivo and in vitro data from Vij and colleagues which highlights CFTR as
a suppressor of basal inflammation acting through NF-kB, a central hub in inflammatory signalling.
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Introduction
Cystic fibrosis (CF) is widely regarded solely as a defect in ion
transport arising from a heritable mutation in the cystic fibrosis
transmembrane conductance regulator (CFTR) [1]. CFTR was
identified nearly 20 years ago [2,3,4] but it remains controversial
as to why defects in this ion channel can cause persistent
pulmonary inflammation given that inflammation may occur in
the absence of recognised CF pathogens [5,6]. Whatever the
mechanism(s), sustained inflammation of the CF epithelium is the
cause of most morbidity and premature mortality in CF patients.
Numerous studies report that signalling through the nuclear factor
kB (NF-kB) pathway, a central hub in inflammatory signalling, is
increased in CF lungs and that this results in excess pro-
inflammatory cytokines such as interleukin 8 (IL-8) [7,8]. One
school of thought believes that this excess is provoked by
underlying infection(s) in the lungs. However, recent data suggest
that an excess of these inflammatory markers may even be present
in the sterile uterine environment of CF fetuses prior to any direct
exposure to pathogens. For example, Verhaeghe et al. showed that
there is increased activation of a number of NF-kB driven genes in
a 24 week old CF fetus compared to non-CF fetuses of similar age
(22 weeks and 23 weeks) [9], whilst others report that in CF and
non-CF human fetal tracheal grafts explanted under the skin of
immuno-deficient ‘SCID’ mice, there was a significantly increased
intraluminal IL-8 content and consistently elevated accumulation
of murine leukocytes in the sub-epithelial region in the CF grafts
compared to controls [10]. These data are consistent with reports
showing increased activation of NF-kB in a variety of CF cell lines
[11,12] where infection is not an issue. In agreement, some studies
have described the presence of neutrophils and elevated levels of
IL-8, in the absence of any detected pulmonary pathogens in
bronchoalveolar lavage fluids of CF newborns as compared to
healthy individuals [13,14]. The combined body of evidence
suggests that the chronic inflammation observed in CF is either
due to some action of the mutant CFTR gene product itself (a
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normal function of the wild type protein (or both may apply). In
this paper we focus on the effects of the wild type protein on the
inflammatory markers NF-kB and IL-8.
Recently Vij et.al. proposed a new role for wild type CFTR
towards inflammation, suggesting that introduction of CFTR to a
previously naı ¨ve cell line was sufficient to significantly reduce basal
IL-8 secretion [15]. Here, we test this idea by examining the
inflammatory consequences of a cell ‘seeing’ wild type CFTR
cDNA either for the first time in transiently transfected CFTR-
naı ¨ve cells or in the context of elevating pre-existing CFTR levels
by transient over-expression above endogenous CFTR baseline
concentrations.
Results
Wild type CFTR specifically suppresses inflammation in a
number of cell lines
To test the proposal that wild-type CFTR (wt-CFTR) could
itself suppress inflammation, a wt-CFTR expressing vector was
transfected into the pulmonary epithelial cell line, H411 as
detailed in the methods to measure its effects on NF-kB activity.
Our H441 clones did not express CFTR as shown by both
Western blot and RT-PCR (figure 1A). The NF-kB activity
observed with empty vector transfection during co-transfection
with a NF-kB driven reporter construct was significantly reduced
by the presence of wt-CFTR with wt-CFTR acting in a dose-
dependent manner resulting in a ,45% reduction in NF-kB
activity after the addition of 400 ng of wt-CFTR vector (p,0.05,
figures 1B, C). Most of the reduction occurred by transfecting as
little as 200 ng of wt-CFTR-encoding plasmid. This significant
reduction in NF-kB activity was mirrored by a significant decrease
in IL-8 in the supernatant (figure 1D) indicating that for this lung
cell line, the cell signalling path from NF-kB to the NF-kB-
response element in the IL-8 gene was wt-CFTR sensitive. Next,
we further explored the idea proposed by Vij et al. whereby active
CFTR contained within lipid rafts at the cell membrane associates
with a TNFa-IL1b-TLR receptor complex to tonically repress
signalling to the NF-kB pathway. Parallel batches of H441 cells
were treated simultaneously with 10 ng/ml TNFa to further
stimulate inflammation. TNFa induced a three fold elevation in
NF-kB activity in the presence of empty vector (figure 1C,
compare heights of first open versus closed bars). Transient wt-
CFTR transfection once again retarded the TNFa-induced
elevation of NF-kB activity, again acting in a dose dependent,
suppressive manner (figure 1C; at 400 ng DNA, TNFa-mediated
elevation of NF-kB activity returned to ‘baseline’). Note that
‘baseline’ now refers to empty vector baseline and not the
depressed levels of NF-kB activity found in figure 1B (compare
heights of last open and closed bars in figure 1C; closed bar data
from figure 1B).
Next, H57 cells were tested because they stably express a NF-kB
driven luciferase construct thus eliminating any potential co-
transfection efficiency issues for the luciferase-based NF-kB
reporter assays reported above. Quantitative real-time PCR was
used to show that these cells also expressed no detectable
endogenous CFTR and that the input of wt-CFTR cDNA once
again produced a dose-dependent increase in CFTR transgene
expression (figure 1E and data not shown). Once again, we
observed a significant ,35% decrease in base line NF-kB-driven
luciferase activity when transfected with 400 ng of a CFTR-
expressing plasmid relative to empty vector alone (figure 1E; n=5,
p,0.05).
To further prove that suppression was a CFTR-specific effect,
the same experiments were performed using a non-CFTR vector
expressing cyano-fluorescent protein (CFP/inset/figure 1F). When
the H57 cells were transfected with increasing amounts of CFP
expressing vector, we found that there was a significant increase in
NF-kB activity of about 20%, further confirming that the
significant reduction in NF-kB activity observed in the presence
of wt-CFTR, is a CFTR specific phenomenon (figure 1F).
The CFTR induced reduction in NF-kB Activity is
dependent on seeding density
During the course of the investigation, we sometimes found the
suppressive effect of CFTR to be much smaller than expected and
wondered if this variability was an effect of initial seeding density
(starting cell number) relative to NF-kB activity. H57 cells were
seeded at 3 different starting densities, each in 12 well plates
(0.5610
5,1 610
5 and 2610
5 cells per well) (inset, figure 2). The
cells were then transfected 24 h after seeding with increasing
amounts of wt-CFTR cDNA supplement to 400 ng with empty
vector as above. In parallel, cells were collected for quantitative
real-time PCR. Only in cells seeded at 1610
5 cells per well (middle
panel, figure 2 inset and open circles in main figure) did NF-kB
activity decline significantly post CFTR (compare decline with
figure 1E). However when expression of CFTR mRNA was
determined, this did not differ between wells (data not shown)
suggesting that the vector was being expressed at all starting cell
numbers (inset, figure 2) but that the cells need to be at certain
combination of seeding density and or confluency for the CFTR
suppressive effect to occur. Confluency may be a factor because by
eye, we noticed that at 2610
5 cells per well, where inflammation
was not suppressed by CFTR, the cells were almost 100%
confluent and thus were presumably contact inhibited, but this
could not have been be the sole explanation because the cell plated
at 0.5610
5 per well were approximately 50% confluent (photo-
micrographs available on request). This suggests the cells might
either require some inter-cell contact or must not be completely
confluent for CFTR to significantly reduce a critical marker of
inflammation. We interpret this data to suggest that CFTR can
but does not always suppress inflammation (see discussion) and
further work will have to establish the relationship between
proliferation and contact inhibition.
Pharmacological inhibition of CFTR increases NF-kB
activation and IL-8 secretion, while channel activation
reduces inflammation
Vij et.al. proposed that CFTR should be active as an ion channel
for the inflammation suppression to occur. CFTRinh172 is a
relatively specific inhibitor of this chloride channel that may
interact with the sixth transmembrane helix in CFTR, probably
preventing pore opening [16]. In a recent study it was shown that
cells that endogenously express wild-type CFTR mimicked the
physiological character of CF cells when treated with this CFTR
inhibitor [17]. These data point to the idea that CFTR channel
dysfunction can itself cause the expression of pro-inflammatory
mediators. Conversely, CFTR channel activity is enhanced, in
part, by cAMP-induced activation of PKA, which phosphorylates
CFTR thereby opening the channel [18]. To check that this
inhibitor was acting in a CFTR specific manner, H441 cells, which
do not express CFTR (figure 1), were transfected with either
400ng of empty vector or 400ng wt-CFTR as above. CFTRinh172
had no significant effect on basal NF-kB activity in the H441 cells
transfected with empty vector (figure 3A, left panels). In contrast,
when wt-CFTR was present the suppressive effect of wt-CFTR
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PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11598Figure 1. Wild-type CFTR attenuates both basal and induced inflammation. A. H441 cells do not express CFTR protein as shown by western
blot or CFTR mRNA as shown by RT-PCR (representative of 3 experiments). B. NF-kB activity in H441 cells transfected with increasing amounts of wt
CFTR cDNA (0–400 ng, n=5, *p,0.01). C. NF-kB activity in H441 cells transfected with increasing amounts of wt CFTR and treated with 10ng TNFa for
4 hours (open bars, n=5, * p,0.001). Closed bars represent basal levels of activity re-drawn from figure 1B. D. The levels of IL-8 in the supernatants
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kB activity induced by the inhibitor (which returned towards the
previously elevated baseline, see discussion). To explore the pro-
inflammatory effect of this inhibitor on endogenously expressed,
rather than transiently transfected CFTR, the normal human
CFTR expressing bronchial epithelial cell line 16HBE14o
2, was
used to ascertain whether either pharmacological inhibition or
PKA-driven activation of CFTR similarly affects inflammatory
markers. 16HBE14o
2 cells were transiently transfected with the
NF-kB luciferase reporter vector as above and 24 h post
transfection, they were treated with either the inhibitor (10 mM
CFTRinh172) and/or the CFTR activator forskolin (10 mM)
together with IBMX (100 mM) to sustain elevated cAMP.
Following addition of CFTRinh172 alone there was a ,31%
increase in NF-kB activation, while treatment with forskolin and
IBMX, which is commonly used to open CFTR by raising cAMP
[19], resulted in a ,25% reduction in NF-kB activity (figure 3B,
third column). Interestingly, when the cells were simultaneously
treated with the inhibitor and the activators of CFTR, NF-kB
activity increased by a similar amount to inhibitor alone (figure 3B
last column) suggesting dominance of channel-inhibition irrespec-
tive of stimuli known to mediate channel-activation (the inhibitor
does not alter [cAMP] [20]). Although IL-8 levels in these
16HBE14o
2 cells were elevated in a similar way to luciferase
activity, the trends in these data were not significantly different
from one another (figure 3C). This was not pursued further.
Instead, we examined the effect of CFTRinh172 on a more
physiologically relevant model by examining the effect of this
CFTR inhibitor on IL-8 secretion in non-CF primary human
nasal epithelium cultured in vitro in submersion culture (figure 3D).
When these cells were treated for 4 h with the inhibitor, there was
an 85% increase in IL-8 secretion demonstrating that this CFTR
dependent mechanism is also relevant in a primary cell model.
We interpret our data (when considered in the context of the in
vivo data from Vij and colleagues) to suggest that pharmacological
inhibition of the residual channel function of CFTR, or the
equivalent inhibition in the presence of PKA-stimulated channel
function, elicit similar pro-inflammatory effects whereas stimuli
known to promote CFTR activation may, conversely, suppress
inflammation but only provided CFTR is active.
Discussion
Our studies arose in part from the finding that when CFTR is
expressed for the first time in the developing fetal lung, the rapidly
rising level of CFTR expression inversely correlated with
endogenous NF-kB activity/IL-8 release coupled to our interest
in lung development [21–25]. Our equivalent data from a lung
cancer cell line suggest that functional wild type CFTR can act as
a brake on inflammation. To model the scope of this phenomenon
under conditions where co-transfection efficiency of our chosen
reporter of inflammation was not confounding, we repeated these
from B were measured by the ELISA method, n=3, * p,0.01. E NF-kB activity (y-axis) in H57 cells transfected with increasing amounts of wt CFTR
cDNA (0–400 ng), n=5, *p,0.05. The amount of CFTR mRNA was then analysed by real-time PCR (qPCR) (x axis). There was no CFTR mRNA detected
in the H57 cells prior to transfection, thus these treatments were allocated the nominal value of zero in all cases. F NF-kB activity in HeLa H57 cells
transfected with increasing amounts of CFP vector (0–400 ng) n=4, *p,0.05. Inset shows CFP levels following transfection with CFP vector.
doi:10.1371/journal.pone.0011598.g001
Figure 2. CFTR only reduces inflammation at a critical seeding density. A. NF-kB activity (n=5, *p,0.05, y-axis) in HeLa H57 cells seeded at
varying densities (0.5610
5,1 610
5 and 2610
5 cells per well; inset), transfected with increasing amounts of wt CFTR cDNA (0–400 ng), relative to
empty vector (100% on y axis). The amount of CFTR mRNA for each transfection as described in methods was then analysed by real-time PCR (qPCR)
(x axis and inset). The inset shows final PCR products from a typical qPCR run showing that there was no detectable CFTR mRNA prior to transfection
with wt-CFTR vector.
doi:10.1371/journal.pone.0011598.g002
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NF-kB driven luciferase vector. Once again the introduction of wt-
CFTR into this CFTR-naı ¨ve setting significantly reduced
endogenous NF-kB activity. This suggests that an anti-inflamma-
tory role of CFTR is a widespread phenomenon with agreement
from in vivo and in cell data when our findings are compared to
Figure 3. Inhibition of CFTR with CFTRinh172.A . NF-kB activity in H441 cells transfected with either empty vector or wt-CFTR (400 ng), each
treated with 10 mM CFTRinh172 for 4 hours, n=3 *p,0.05 (compared to empty vector control),
#p,0.05 (compared to CFTR control). B. NF-kB activity
in 16HBE14o
2 cells treated with 10 mM CFTRinh172 and/or 10 mM forskolin and 100 mM IBMX for 4 h, n=7, *p,0.05. C. IL-8 levels in supernatants from
16HBE14o
2 cells measured by ELISA, n=8, p not significant. D IL-8 levels in supernatants from primary human nasal epithelial cells treated with
10 mM CFTRinh172 for 4 hours, n=4, *p,0.05.
doi:10.1371/journal.pone.0011598.g003
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despite the fact that all our work was undertaken on undifferen-
tiated sub-confluent cells in submersion culture where we cannot
conclude that (open or closed) CFTR was present at an apical
membrane or in a particular lipid raft fraction as proposed by Vij
and colleagues. Given that CFTR is expressed widely and not just
in epithelial cells, our work might have relevance to other cells
within the immune system that could play a role in in vivo
inflammation in CF. Furthermore, in the presence of a relatively
specific CFTR inhibitor, we observed an increase in inflammatory
markers and conversely, when cAMP was elevated there was a
decrease of a similar magnitude below baseline (provided the
CFTR inhibitor was absent). The absolute amount of CFTR
mediating this effect may be critical to this regulation because the
inflammatory markers decreased in a dose-dependent manner
with increasing wt-CFTR transfection suggesting that the lack of a
threshold level of CFTR is itself an important pro-inflammatory
signal. A most interesting finding was that the level of CFTR-
induced suppression after TNFa was applied was such that NF-
kB-driven luciferase activity only returned to basal levels (found
before the stimulus was applied) and never reached the hyper-
suppressed nadir observed in the absence of TNFa. These data
from figure 1C suggest that CFTR can act both as a suppressor of
basal and stimulated inflammation, but in the latter case, CFTR
only acts as a post-stimulus, buffer to restrain the magnitude of rise
of inflammation following a pro-inflammatory stimulus. This
notion is consistent with the frequently observed clinical scenario
where CF patients can remain well for prolonged periods but
nevertheless succumb rapidly post-infection with a sustained rise in
inflammation that fails to abate without therapy; an established
clinical observation which we explain by suggesting that the loss of
wt-CFTR in a CF patient prevents a return to baseline
inflammatory signalling. With the caveat that we studied non-
polarised cells, wt-CFTR may also need to be ‘active’ because
firstly, we find that elevating cAMP suppresses inflammatory
markers by about 25% and secondly, that treatment with a specific
inhibitor of channel function (CFTRinh172) [17], resulted in an
increase in NF-kB activity only when wt-CFTR was present
(figure 3A). Furthermore, when cells endogenously expressing
CFTR were treated with this inhibitor, it not only negated the
decline in inflammation found after pharmacological elevation of
cAMP but also acted dominantly over our cAMP-elevating
cocktail and, separately, in cultured, wt-CFTR expressing primary
human nasal cells, induced a near doubling of IL-8 secretion
without prior CFTR-stimulation. The repeated dose-dependency
of our suppressive findings suggest that wild-type CFTR acts as an
expression-level dependent, anti-inflammatory protein. Further-
more, given the reciprocal effects of pharmacological CFTR
inhibition (pro-inflammatory) and activation (anti-inflammatory)
giving rise to a near 50% difference in levels of a critical hub in
inflammation, we concur with Vij et al that that the inflammation
suppressive action of wt-CFTR might require an active channel.
This may also be relevant to the post-stimulus level of
inflammation because of our finding that when cells are stimulated
with TNFa, they are much less pro-inflammatory in the presence
of wt-CFTR; the latter again acting in a dose-dependent manner
suggesting that wt-CFTR suppresses not only basal inflammation
but also down regulates TNFa stimulated inflammation
(figure 1C). Given that CFTR mRNA is expressed up to 70 times
higher in fetal lung than in adult [22], it may be that changes in
CFTR levels at the cell membrane can suppress inflammatory
pathways. This should not be a surprise as after all, inflammatory
pathways found in adult life operate in development to control cell
growth and differentiation [23,24,25]. Our finding that starting
cell number i.e. initial cell density might also be an important
signal might also be relevant to the above fetal data where lung
cells are rapidly dividing as the lung grows. Importantly, our
conclusions are not confounded by differences in transfection
efficiency of reporter constructs because they are reproduced to
the same degree in HeLa cells stably expressing the NF-kB driven
luciferase vector. Crucially, our study independently verifies recent
work by Vij and colleagues [15] who showed that re-introduction
of wild-type CFTR into a kidney epithelial cell line (HEK293) or,
in a disease context, human bronchial epithelial cells expressing
the common DF508-CFTR (Phe508del) mutation (CFBE41o-)
suppresses not only basal NF-kB activity but also had robust
inhibitory effects on IL1b-induced chemokine (IL-8) expression
[15]. They further demonstrated that exposure to lipopolysaccha-
ride (LPS) evoked a greater immune response in a viable murine
CFTR knockout model compared to wild-type animals. Although
their experiments also suggest that CFTR functionally suppresses
inflammation in vivo, the corroborating evidence from cell lines
used in their study, when compared to our own data, suggests that
the means by which a cell controls the level of wild type CFTR
must now be considered as an important contributor, if not a key
cause, of inflammation. Thus, we concur that wild type CFTR has
an anti-inflammatory function acting through an NF-kB hub that
is aberrant in cells expressing mutant CFTR, probably because the
most common Phe508del CFTR is .90% degraded, i.e. wt-
CFTR is not present as a restraint on inflammation. Although
neither study establishes how this suppression of inflammation
might occur, each independently verifies that inhibition of CFTR
conductance using CFTRinh172 mimics the pro-inflammatory
effects of the absence of CFTR. Thus, functional CFTR is key
to suppressing inflammation. Vij et al. propose a model in which
active CFTR contained within lipid rafts at the cell membrane
associates with TNFa-IL1b-TLR receptors and so tonically
represses signalling to the NF-kB pathway. Removal of CFTR
relieves this repression and so raises basal activity of the NF-kB
pathway. We do not disagree but what exactly constitutes ‘basal’
NF-kB activity is a moot point. Our unpublished data shows that
lipofectamine alone when administered to H57 cells for 24 hours
induces a significant ,20% decline in NF-kB activity and this
represents a new lower ‘baseline’ compared to lipofectamine-naı ¨ve
H57 cells. Empty vector did not alter this decline, CFTR made the
decline more intense and CFP returned the basal activity towards
this original lipofectamine-naı ¨ve ‘baseline’. Thus the concept of
baseline inflammation requires further study because NF-kB might
signal differently in each different ‘baseline’ scenario.
By deliberate intent, our study did not focus on mutant forms of
CFTR because the literature is confused and the very existence of
inflammation when mutant CFTR is present remains controver-
sial. A number of studies have shown higher expression and
secretion of various inflammatory mediators in CF cells compared
to wild-type cells, but these are not always homologous CFTR-
expressing cells [11,17,26,27,28,29,30,31,32,33]. As a result, there
is a great deal of variation between cell lines; different groups have
measured a variety of markers in a number of ways and results
vary even in the same cell lines, perhaps, as we show here, due to
different culture conditions or seeding densities. If inflammation
arises from the absence of a basal suppression of inflammation by
wt-CFTR, this loss of suppression may operate alongside the
positive pro-inflammation function for mutated CFTR reported
by many groups. Thus, lung cells expressing high levels of wt-
CFTR may be less inflamed than those that express little or no
CFTR protein leading us to consider that inflammation decreases
in proportion to the amount of wt-CFTR. It has proven difficult to
dissect out the pleiotropic effects of CFTR mutants with effects
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and unfolded protein response [34]. For example, under highly-
expressing cell conditions, much Phe508del-CFTR fails to traffic
properly, and it is expressed in very low levels at the airway surface
cell membrane (as opposed to glands). Even this ‘long-established’
idea is controversial because some find mutant CFTR is not
mostly degraded [35]. Our data predict that the higher
inflammation in CF cells could be a consequence of fewer wt-
CFTR molecules at the membrane, as would be predicted to occur
with stop mutants such as G542X that occur in a minority of CF
patients and the clinical data supports the view that the presence of
CFTR mutants such as G551D-CFTR that traffic normally but
fail to transport chloride at all, nevertheless reduce lung damage to
a degree [36]. This idea is also consistent with reports of the effects
of some CFTR ‘correctors’. These drugs increase CFTR
expression at the membrane (for example, MPB-07, miglustat
and NB-DGJ) and some can reduce the inflammatory response of
cells to Pseudomonas aeruginosa [37,38]. With the compounds
miglustat and NB-DGJ, this reduction was observed in both CF
and non-CF cells. Although both these compounds reduced
inflammation, NB-DJG did not restore CFTR pore activity in the
CF cells, suggesting that the effects of CFTR on inflammation may
be separate from channel opening/closing. These data are also in
agreement with the observations of Weber et al., who showed that
NF-kB activation and IL-8 secretion were increased in
16HBE14o
2 cells expressing CFTR antisense construct (com-
pared with those expressing CFTR sense) and in a corresponding
experiment in human tracheal cells comparing 9/HTEo
2/pCep-
R cells with 9/HTEo
2/pCep [33]. In fetal life, CFTR is expressed
in the lungs at around 12 weeks gestation, however in the CF fetus
Phe508del CFTR expression may be delayed for about 3 weeks
[21] and our data predict that NF-kB may be dysregulated for that
period. This is in agreement with both Jacquot and colleagues,
who find evidence for NF-kB dysfunction in human fetal tracheal
grafts in SCID mice [10], and Verhaeghe et al. who showed
increase expression of various inflammatory markers in human CF
fetal lung at 24 weeks gestation [9].
The inhibitor CFTRinh172 increased the (lipofectamine, see
above) baseline activation of NF-kB and increased IL-8 secretion
in 16HBE14o
2 cells, which is in agreement with Perez et al., who
showed that inhibition of CFTR with CFTRinh172 increased
secretion of IL-8 in 16HBE14o
2 cells [17]. CFTRinh172 is thought
to prevent channel opening of CFTR and thus abrogate the
chloride current. Recent data, from mutation analysis of critical
residues, suggests the inhibitor may act directly on CFTR within
the sixth transmembrane helix of the protein, a domain that has an
key role in the channel pore formation at arginine 347 [16]; but
exactly how the inhibitor acts on CFTR is not fully understood.
For example, recently Kelly and colleagues put forward evidence
that CFTRinh172 had effects on mitochondrial function indepen-
dent of CFTR [39]. They showed that the inhibitor induced rapid
increases in reactive oxygen species (ROS) levels and depolariza-
tion of mitochondria in 4 different cell types independent of the
presence of CFTR. In HeLa cells with no CFTR present, they
found treatment with CFTRinh172 increased translocation of NF-
kB to the nucleus and a slight increase in IL-8 secretion. However
in our hands with the H441 cell line where with no CFTR present
we found that there was no significant change in NF-kB activity
when treated with the inhibitor, however when CFTR was present
there was a significant increase in NF-kB activity, suggesting that
the effects of the inhibitor may differ between cell lines, depending
on which pathways remain intact (compare figure 3C with 1D). In
our hands, treatment with forskolin and IBMX, which normally
strongly activates PKA, resulting in opening of the CFTR pore,
significantly reduced inflammation in 16HBE14o
2 cells, indicat-
ing that activity of the channel may be required to reduce
inflammation. However when CFTRinh172 is added, the decrease
in inflammation induced by cAMP is completely abrogated.
Recent data suggest that CFTR interacts with the TNF receptor
TNF-R1 in lipid rafts and modulates IL-8 secretion and gap
junction formation [40]. There is also evidence that TNF-R1 is a
modulator of CF as there is an association between polymorphisms
in the TNF-R1 gene and disease severity [41]. We conclude that
CFTR modulates downstream signalling (perhaps from TNF-R1)
and suggest that CFTR controls release of inflammatory
molecules, resulting in suppression of inflammatory signalling.
Since our recent work suggests that CFTR creates a membrane-
anchored hub controlling the membrane localisation of at least
four different protein kinases, [19,42,43,44,45,46], the loss of wild
type CFTR at the membrane is predicted to disrupt multiple
pathways given that all these protein kinases have been implicated
in inflammatory signalling. Further work will have to establish how
the dysfunction of this signalling system when mutant CFTR is
degraded, leads to multiply disrupted protein kinase cascades,
which others have implicated in inflammation [47].
In conclusion, we confirm that expression of exogenous CFTR
has a powerful anti-inflammatory effect and that inducers and
inhibitors of CFTR function modulate this effect. Different
laboratories now agree that the very presence of wild type CFTR
suppresses inflammation, making the topic worthy of study.
Restoring the mechanism of suppression may help alleviate the
commonest cause of lung destruction and morbidity in this disease.
Materials and Methods
Ethics Statement
This work was approved by Tayside Committee on Medical
Research Ethics Ref 011/91.
Materials
All tissue culture media and antibiotics were purchased from
Sigma Aldrich, Gillingham U.K., fetal calf serum was purchased
from Invitrogen, Paisley, U.K. All chemicals were purchased from
Sigma Aldrich unless otherwise stated.
Cell Culture
NCI-H441 cells, a human lung adenocarcinoma cell line of
bronchiolar (Clara) cell lineage (obtained from the American Type
Culture Collection (ATCC) HTB-174), were grown on plastic
tissue culture dishes in RPMI 1640 medium containing 10% fetal
bovine serum, penicillin (100 u/ml), streptomycin (100 mg/ml) in
a humidified CO2 incubator (37uC, 5% CO2). H57 cells, a HeLa
cell derived cell line which stably over expresses the NF-kB
luciferase construct (courtesy of R. Hay, Dundee, UK) [48], and
16HBE14o
2 cells, a human normal bronchial epithelial cell line
provided by D. Gruenert, San Francisco, CA, U.S.A [49] were
grown on plastic tissue culture dishes in Eagle’s minimum essential
medium containing 10% fetal bovine serum, penicillin (100 u/ml),
streptomycin (100 mg/ml). All tissue culture media and antibiotics
were purchased from Sigma Aldrich, Gillingham U.K., Fetal calf
serum was purchased from Invitrogen, Paisley, U.K.
Primary nasal epithelia were grown on plastic tissue culture
dishes in BEBM medium (Clonetics) with all Singlequot
supplements except EGF and gentamicin, supplemented with
1 mM CaCl2, 100 ml of the EGF Singlequot, penicillin (100 U/ml)
and streptomycin (100 mg/ml) (Sigma). Ethical permission and
written consent were obtained.
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For luciferase assay cells were seeded in 12-well plates. The 4-kB-
luciferase reporter plasmid contained four NF-kB binding elements
39 (TGGGGACTTTCCGC) 59 upstream of the thymidine kinase
minimal promoter region that drove expression of the firefly
luciferase reporter gene. H441 and 16HBE14o
2 cells were
transfected with 400 ng of 4-kB-luciferase reporter plasmid using
lipofectamine 2000 reagent (Invitrogen, Paisley, UK). H441 cells
were transfected with 0–400 ng wt-CFTR and to to rule out a DNA
dose effect, transfections were supplemented with empty vector
plasmid to keep total DNA constant (for example, the 100 ng
transfection of CFTR contained 300 ng of empty vector) during co-
transfection with a NF-kB driven luciferase construct (both using
lipofectamine as vehicle). H57 cells were treated as H441 cells
excluding the luciferase vector. 24 h post transfection, cells were
treated with combinations of 10 ng/ml TNFa, to stimulate NF-kB
activity, 10 mM CFTRinh172 (Merck, Nottingham, U.K.), to inhibit
CFTR and 10 mM Forskolin and 10 mM IBMX to stimulate PKA
by elevating cAMP. All treatments were for 4 h, after which
supernatants were retained for IL-8 ELISAs and cells were lysed in
luciferase lysis buffer (10 mM KH2PO4, 1 mM EDTA, 10 mM
MgCL2,5 0m Mb-glycerophosphate, 5 mM EGTA, 0.5% Igepal,
0.1% Brij35, 1 mM Sodium Orthovanadate and Protease inhibitor
cocktail). Reporter gene activity was determined using the luciferase
assay system (Promega, Southampton, U.K.).
IL-8 ELISAs
The concentration of IL-8 in supernatants was determined by
ELISA according to the manufacturer’s recommendations (Mast
Diagnostics, Bootle, U.K.) with appropriate standard curves.
Results were normalised for protein content.
Immunoblotting
Cell lysates were run on 4–12% Novex gels using the MOPS
buffer system (Invitrogen UK). Following transfer membranes
were blocked in Tris-buffered saline with Tween (TBST) with 5%
milk and probed with CFTR Ab-3 (L12B4) antibody (Neomarkers,
CA, USA.).
Reverse Transcription
RNA was extracted using RNeasy Mini Kit (Qiagen, Crawley
West Sussex, U.K.). Using 1 mM of oligo dT15 primer (Promega,
Southampton, U.K.), 2 ml of 5 mM dNTPs, 10 u RNasinH Plus
RNase Inhibitor (Promega, Southampton, U.K.) with 4 u of
Omniscript reverse transcriptase (Qiagen, Crawley West Sussex),
1 mg of RNA was reverse transcribed by incubating the reaction
mixture for 60 min at 37uC.
PCR
PCR of the cDNA was then carried out using Gotaq green
(Promega,Southampton,U.K.)and theCFTRspecificprimers,exon
9, HCF21: 59-TTGCTGGATCCACTGGAGCAGG-39; exons 12–
13, HCF22: 59-GCCATCAGTTTACAGACACAG-39 which pro-
duces a 421bp fragment [50]. 10 ml of each PCR product was run on
1.5% Agarose gels. Negative controls for cDNA synthesis were run
without template and also without reverse transcription.
Real-Time PCR
Real-time PCR(qPCR) was performed using SYBR Green
based detection on a Rotor-Gene Q machine (Qiagen) with each
20ml reaction containing approximately 30 ng cDNA, 16Quanti-
Tect Primer assay (CFTR or B2M) ( Quiagen) and 16Rotor-Gene
SYBR Green PCR master mix (Qiagen). Samples were cycled
under the following conditions: 95uC/5min, 50 cycles of 60uC/
14 s and 95uC/7 s. each reaction was performed in duplicate,
mRNA levels for B2M were used for normalization and fold
induction was determined from Ct values using Pfaffl method [51].
PCR efficiency was determined from the slope of a standard curve
generated using fivefold dilution series of DNA template.
Efficiency values for CFTR 1.01, B2M 1.17, R value of slopes
CFTR 0.988 and B2M 0.998.
Statistics
Statistical significance was assessed relative to control groups
using an unpaired Students T-test.
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